ABCC3 and metabolic dysfunction-associated steatotic liver disease: Indeed, CYPA2 is downregulated, whereas CYP2E1 and the efflux transporter MRP3 are upregulated, potentially inducing high variability in the OAC bioavailability in patients with NAFLD (11, 42).